BD&L Diligence Dossier
30-second diligence on any drug or target: biology, clinical stage, safety, patents, funding, literature, and revenue signals.
The problem this solves
Life sciences teams need decisions faster than public data can be cleaned manually. This solution compresses months of preparation into a governed, query-ready product.
VP-level and director-level teams often know which questions matter, but the required data is spread across incompatible FDA, CMS, NIH, EMA, USPTO, literature, ontology, and identity sources.
BD&L Diligence Dossier removes the repeated engineering work by delivering the connected tables, bridge keys, and sample queries that your team would otherwise build from scratch.
What you get
Asset and target evidence cards that combine mechanism, clinical phase, target-disease score, and literature momentum.
Competitive trial landscape, sponsor normalization, patent runway, and safety signal summaries in the same schema.
NIH funding, publication, and disease ontology context for external innovation and indication strategy.
Query-ready diligence outputs for BD, search-and-evaluation, and corporate strategy workflows.
Context Layers Powering This Solution
Each card links to a query-ready context layer in the biomedical estate.
Drug-target mechanism and bioactivity context
Scientific layer • 2.5M compounds • Quarterly
Scientific contextHuman protein target biology context
Scientific layer • 20,370 human proteins • Quarterly
Disease & Ontology contextTarget-disease evidence and druggability context
Disease & Ontology layer • 7.5M target-disease associations • Quarterly
Clinical contextActive and historical trial landscape context
Clinical layer • 519K+ trials • Weekly
IP & Patent contextListed patent runway and challenge context
IP & Patent layer • 15K+ patents • Monthly
IP & Patent contextPatent family, assignee, and citation context
IP & Patent layer • 8M+ patents • Quarterly
Regulatory contextPost-market adverse-event signals and safety reporting context
Regulatory layer • 25M+ reports • Quarterly
Clinical contextResearch funding momentum and grant linkage context
Clinical layer • 1.27M grants • Annual
Literature contextBiomedical literature evidence context
Literature layer • 10.2M papers • Monthly
Clinical contextEuropean authorization and dual-market context
Clinical layer • 1,500+ products • Monthly
Disease & Ontology contextCross-ontology disease mapping context
Disease & Ontology layer • 25K+ terms • Quarterly
Day-one query results for KRAS G12C
Designed sample output showing the type of redacted table your analysts can query immediately after provisioning.
| Signal | Value | Source |
|---|---|---|
| Canonical entity | KRAS G12C | Drug spine |
| Primary risk score | High confidence | Pre-computed model |
| Connected products | 11 products | TDD catalog |
| Latest refresh | 2026-09-01 | Lineage table |
Built for the teams who own the decision
For BD&L teams
Screen target or asset opportunities before deep diligence starts and prioritize the highest-signal assets.
For Search and evaluation teams
Compare mechanisms, trial progress, funding intensity, safety burden, and IP runway across targets.
For Corporate strategy teams
Build thematic landscapes around diseases, modalities, platforms, and external innovation clusters.
Common questions
Procurement, architecture, and analytics teams can evaluate exactly how the product will land in your environment.
Query on day one
Sample SQL included
Is the dossier generated from public data only?
Yes. It uses public biomedical authorities and does not require proprietary, patient-level, or confidential data.
Can we customize the scoring weights?
Yes. Core tables are delivered query-ready, and customers can adjust prioritization logic inside their own warehouse.
Does it include target biology?
Yes. ChEMBL, UniProt, Open Targets, disease ontology, publications, and funding data are connected through target and disease identifiers.
See This Solution In Action
We'll walk through live warehouse queries and sample outputs for your specific use case.
Request Demo